Melanoma gp100 Antibody (YA5749)

Cat. No.: HY-P86057: Data Sheet User Guide for Antibodies
FAQs
Technical Support

Melanoma gp100 Antibody (YA5749) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Melanoma gp100.

For research use only. We do not sell to patients.

Size	Stock	Quantity
20 μL	Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 μL	Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 μL	Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
250 μL	Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

Melanoma gp100 Antibody (YA5749) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Melanoma gp100.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 70 kDa;

Observed band size: 80 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse

SwissProt ID

P40967

Gene ID

P01241 [NCBI] / P0DML2 [NCBI] / P0DML3 [NCBI]

Immunogen

Synthesized peptide derived from human PMEL AA range: 400-500

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:200-400
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:500-5000

Purity	affinity chromatography.	Conjugation	Non-conjugated
Modification	Unmodified	Isotype	IgG1

Appearance

Liquid

Formulation

Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Forms physiological amyloids that play a central role in melanosome morphogenesis and pigmentation. The maturation of unpigmented premelanosomes from stage I to II is marked by assembly of processed amyloidogenic fragments into parallel fibrillar sheets, which elongate the vesicle into a striated ellipsoidal shape. In pigmented stage III and IV melanosomes, the amyloid matrix serves as a platform where eumelanin precursors accumulate at high local concentrations for pigment formation. May prevent pigmentation-associated toxicity by sequestering toxic reaction intermediates of eumelanin biosynthesis pathway; Represents a potent melanoma-specific antigen. Among melanoma non-mutated self-peptides, G9-154 (KTWGQYWQV), G9-209 (ITDQVPFSV) and G9-280 (YLEPGPVTA), appear to act as immunodominant common epitopes that stimulate anti-tumor immune response mediated by HLA-A-restricted cytotoxic T cells

Subcellular Localization：Endoplasmic reticulum membrane; Single-pass type I membrane protein; Golgi apparatus, cis-Golgi network membrane; Single-pass type I membrane protein; Endosome, multivesicular body; Melanosome; Extracellular vesicle; Secreted

Expression：
Tissue_specificity:It is typically expressed at low levels in quiescent adult melanocytes, but is overexpressed in proliferating neonatal melanocytes and during tumor growth. It is also overexpressed in melanoma. Some expression has also been found in dysplastic nevi.

Isoforms & Post-Translational Modification：P40967 has 5 isomers: P40967-1: 70255 Da (predicted); P40967-2: 70949 Da (predicted); P40967-3: 60581 Da (predicted); P40967-4: 66035 Da (predicted); P40967-5: 66729 Da (predicted).
N- and O-glycosylated. A small amount of P1/P100 (major form) undergoes glycosylation in ER and Golgi compartments to yield P2/P120 (minor form). The mature P2 form leaves the trans-Golgi network and is mainly targeted to stage I melanosomes via the plasma membrane and clathrin-mediated endocytosis. Stage II melanosomes harbor only Golgi-modified fragments that are derived from M-alpha and that bear sialylated O-linked oligosaccharides. O-glycosylation of the RPT region is a conserved feature likely involved in amyloid sheet separation via electrostatic repulsion;Undergoes multiple proteolytic processing. In a post-Golgi prelysosomal compartment, P2 is cleaved by a furin-like proprotein convertase (PC) into two disulfide-linked subunits: a large lumenal subunit, M-alpha/ME20-S, and an integral membrane subunit, M-beta. Despite cleavage, only a small fraction of M-alpha is secreted, as most M-alpha and M-beta remain associated with each other intracellularly via a disulfide bond (PubMed:11694580, PubMed:12732614, PubMed:15096515, PubMed:15695812, PubMed:17991747). Once targeted to stage I melanosomes, beta-secretase BACE2 cleaves the M-beta fragment to release the amyloidogenic luminal fragment containing M-alpha and a small portion of M-beta N-terminus (PubMed:23754390). M-alpha is further cleaved by metalloproteinases, likely ADAM10 or ADAM17, and still unknown proteases to yield subfragments that ultimately assemble into amyloid fibrils (PubMed:19047044). The C-terminal fragment of M-beta is processed by the gamma-secretase complex to release a short intracytoplasmic domain (PubMed:19047044)

Subunit：Homodimer; disulfide-linked. Dimerization in the endoplasmic reticulum and early Golgi prevents premature fibril formation. The dimers are resolved to monomers in late- or post-Golgi compartments (PubMed:26694611). Heterooligomer; amyloid-type. Processed amyloidogenic fragments assemble into fibrils that further organize into beta-sheet quaternary amyloid structures (PubMed:28272432, PubMed:30988362). Interacts (via luminal C-terminal fragment) with CD63; this is important for sorting of the luminal fragment in tetraspanin rich microdomains in stage I melanosomes to prevent premature lysosomal degradation (PubMed:21962903). Interacts with APOE; this allows the loading of the luminal fragment on ILVs to induce fibril nucleation (PubMed:26387950). Interacts with MLANA (PubMed:15695812)

Synonyms

95 kDa melanocyte specific secreted glycoprotein; 95 kDa melanocyte-specific secreted glycoprotein; D12S53E; gp100; M-beta; ME20; ME20 M/ME20 S; ME20-M; ME20-S; ME20M; ME20M/ME20S; ME20S; Melanocyte lineage specific antigen GP100; Melanocyte protein mel 17; Melanocyte protein Pmel 17; Melanocyte protein Pmel 17 precursor; Melanocytes lineage-specific antigen GP100; Melanoma associated ME20 antigen; Melanoma gp100; Melanoma-associated ME20 antigen; Melanosomal matrix protein 17; Melanosomal matrix protein17; P1; p100; p26; PMEL 17; PMEL; PMEL_HUMAN; PMEL17; Premelanosome protein; Secreted melanoma-associated ME20 antigen; SI; SIL; SILV; Silver; mouse homolog; like; Silver homolog; Silver locus protein homolog; HMB45;

Documentation

User Guide for Antibodies (1077 KB)